Animal models that mimic advanced prostate, breast, or non-small cell lung cancer, representing both osteolytic and osteoblastic skeletal lesions, have demonstrated that the RANKL inhibitors, RANK-Fc or OPG-Fc,were effective in preventing or delaying of bone metastases and reducing progression of tumours in the skeleton (132). The gene discussed is TNFRSF11A; the disease is neoplasm.